ksd-101
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2023 (NCT06097793)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- epstein-barr virusINHIBITOR
epstein-barr virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06752473 | Early Phase 1 (Phase 1) | Jan 31, 2025 | Kousai Bio Co., Ltd. |
| NCT06370026 | Early Phase 1 (Phase 1) | May 1, 2024 | Kousai Bio Co., Ltd., Sun Yat-Sen University |
| NCT06097793 | Early Phase 1 (Phase 1) | Nov 1, 2023 | Huazhong University of Science and Technology, Kousai Bio Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kousai Bio Co., Ltd. | For profit | 3 | 2 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1